Neurofeedback for Nociplastic Pain in Rheumatoid Arthritis (NECTAR)

Rheumatoid Arthritis Clinical Trial

— NECTAR  

Official title:

Neurofeedback for Nociplastic Pain in Rheumatoid Arthritis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06240299
• Other study ID #: UGN23NE390
• Status: Not yet recruiting
• Phase: N/A
• Start date: February 1, 2024
• Est. completion date: May 31, 2025

Study information

• Verified date: February 2024
• Source: NHS Greater Glasgow and Clyde
• Contact: Aleksandra Vuckovic, PhD
• Phone: 07906441955
• Email: aleksandra.vuckovic[@]glasgow.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Rheumatoid arthritis is an autoimmune condition, causing inflammation and pain. Yet pain may persist even when inflammation has been treated. This residual pain, called nociplastic pain, has symptoms of a chronic pain condition called fibromyalgia. There are few effective therapies to address this residual pain. Published literature shows that fibromyalgia can be treated by neurofeedback, a noninvasive method that is based on the voluntary modulation of cortical activity. In this pilot study, the investigators want to test the effect of neurofeedback on the fibromyalgia component of pain in rheumatoid arthritis, and also to investigate its effects on related symptoms such as fatigue and sleep disturbance.

Description:

Study Schedule For each participant, the intervention paradigm consists of a 1-week diary of pain, sleep and fatigue prior to baseline assessment, 10 intervention sessions 2-3 times per week, post-intervention assessment and remote post-intervention follow-up interview, one month after the last intervention. Hence, each participant will be enrolled in the study for 11-13 weeks, including the follow-up assessment. In case of short-term health problems (e.g., Covid 19, flu, seasonal allergy, etc), experimental sessions can be postponed for up to one week. A maximum of two sessions can be missed otherwise participants will be withdrawn from the study.

Intervention EEG will be recorded with one unit (16 channels) of a modular EEG device (usbamp, Gtec, Austria) requiring 5-10 min setup. Before neurofeedback training (NF), daily baseline EEG activity will be recorded for 2 min, during which participants will sit in a relaxed state, with eyes open. After that, participants will see a graphical user interface (GUI) consisting of three bars that correspond to signal power in three frequency bands: theta, alpha and beta. The bars change colour and height proportionally to the band power. Participants will be aiming to decrease theta and beta and to increase alpha band power as compared to the baseline values. If the power of a particular band passes the threshold level set by the daily baseline recording, the corresponding column turns green, otherwise, the colour is red. NF will be provided from the sensorimotor cortex (electrode locations C4/C3). In total, each training session lasts for 30 min. A second, 2min long EEG recording in the relaxed state with eyes opened will be recorded immediately after the NF session. The experimenter will advise participants on successful mental strategies in the first 3 sessions and will let participants choose their preferred strategy during sessions 4-10.

Baseline EEG recording Participants will be comfortably sitting approximately 1 meter from a computer screen. EEG will be recorded with 4 units (64 channels, passive electrodes) of modular multichannel EEG. This setup requires up to 30 min. EEG will be recorded for 8 min in alternative 2 min blocks of relaxed eyes open and eyes closed state. During eyes open recording, they will be asked to look at a cross in the centre of the screen to avoid excessive eye movements. Following this, participants will be asked to perform cue-based motor imagination practice, i.e., to imagine moving their left and right hands and feet every time they see a cue on a computer screen. Cues will appear in semi-random order, each cue appearing 60 times. A total of 180 trials will be split in six sub-sessions, each totalling 30 trials (10 right hand, 10 left hand, 10 feet).

Quantitative Sensory Testing Quantitative Sensory Testing (QST) is a standardised methodology to study pain sensitivity in humans. A QST protocol includes a series of noxious and non-noxious stimuli delivered to a patient, followed by a semi-objective method for the patient to rate their perception of each stimulus. In this study, participants will complete an abbreviated QST battery to characterise pain sensitivity. All participants who consent to this procedure will undergo familiarisation training prior to data collection to reduce QST-related anxiety. QST comprise of pressure pain sensitivity test and cuff algometry test. Pressure pain sensitivity (15-20 minutes) will be assessed using a digital algometer with a 1 cm2 rubber probe to quantify pressure pain thresholds (PPT) at multiple body sites. Pressure will be manually increased up to 1000 kilo Pascals (kPa). Cuff algometry (10 minutes) will be used to measure deep muscle tonic pain. This consists of a computer controlled air compressor which delivers varying degrees of pressure to a Velcro-adjusted cuff applied to one gastrocnemius muscle.

Visit 1 (week 0): Screening, Consent, Baseline EEG , Questionnaires and Research assessments (including QST). The total duration of Visit 1 will be 4-5 hours including comfort breaks and time for EEG setup.

Visits 2-11 (weeks 1-5): Neurofeedback sessions 1-10, Pain questionnaires (structured and semi-structured). The study visit, including EEG setup (time to put it on and off), intervention and debriefing will take 60-70 min.

Visit 12 (week 6): post-intervention EEG, Questionnaires and Research assessments (including QST). This assessment will take place within 7 (±5) days after the last NF session. The total duration of Visit 12 will be 4-5 hours including comfort breaks and time for EEG setup.

Visit 13 (week 10): remote follow-up. A 10 min semi-structured interview, covering topics such as pain, sleep, fatigue and any adverse effects. The interview will take place over the phone.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 16
• Est. completion date: May 31, 2025
• Est. primary completion date: March 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Fulfilment of the ACR/EULAR Classification Criteria for rheumatoid arthritis (RA)

• Fulfilment of the American College of Rheumatology criteria for chronic widespread pain

• Stable disease (swollen joint count =1 and CRP =10)

• Has normal or corrected to normal vision and hearing abilities

• Right-handed (to reduce baseline motor response test heterogeneity)

• Pain intensity equal or larger than 4 on the Visual Numerical Scale (0 no pain, 10, max pain imaginable)

Exclusion Criteria:

• Unable to understand the task.

• Unable to provide a written informed consent.

• Unable to understand English.

• Major confounding neurological diseases including Multiple Sclerosis, Stroke, Traumatic Brain Injury, Parkinson's Disease, and Alzheimer's Disease)

• Medical or psychiatric conditions that in the judgment of study personnel would preclude participation in the study (psychosis, suicidal ideation etc)

• Under active management of pain team (changing medications, other non pharmacological pain treatment)

• Involved in other interventional experimental studies

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Chronic Widespread Pain
• Rheumatoid Arthritis

Intervention

Procedure:
• Neurofeedback
A noninvasive method based on the voluntary modulation of brain activity, with feedback provided through a graphical user interface shown on a computer screen

Locations

Country	Name	City	State
United Kingdom	Clinical Research Facility (CRF), Queen Elizabeth University Hospital	Glasgow	Scotland

Sponsors (2)

Lead Sponsor	Collaborator
NHS Greater Glasgow and Clyde	University of Glasgow

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in nociplastic pain (Visual Analog Scale)	Difference in nociplastic pain following 10 sessions of neurofeedback, compared to baseline, as measured by a on a 10 point Visual Analog Scale (VAN), from 1 to 10, where 10 is the highest possible pain. Improvement is indicated by a reduction in score.	4 weeks
Secondary	Difference in nociplastic pain (ACRFS)	Difference in nociplastic pain following 10 sessions of neurofeedback, compared to baseline, as measured by the American College of Rheumatology Fibromyalgia Scale (ACRFS). The score ranges between 0-19, with improvement indicated by a reduction in score.	5 weeks
Secondary	Difference in nociplastic pain (ACRFS) 1 month post-intervention	Difference in nociplastic pain 1 month after the last session, compared to baseline, as measured by the American College of Rheumatology Fibromyalgia Scale (ACRFS). The score ranges between 0-19, with improvement indicated by a reduction in score.	10 weeks
Secondary	Success of performing neurofeedback	EEG power in theta (4-8 Hz), alpha (8-12 Hz) , low beta (13-20 Hz), high beta (20-30) and gamma (30-45 Hz) during NF compared to daily baseline, to assess the success of performing neurofeedback	5 weeks
Secondary	Mental strategies during neurofeedback	Self-reported mental strategies (a goal-directed mental action performed in order to control the graphical user interface) and affects (emotional experience e.g.happy, excited, frustrated, anxious etc.) during NF	5 weeks
Secondary	Multidimensional Health Locus of Control Scale	Questionnaire that evaluates the quality of life in patients with diseases or disabilities, containing 18 questions or statements. For each statement, the participant rates their level of agreement on a 6 point scale, from strongly disagree, to strongly agree.	6 weeks
Secondary	NASA task load index	Questionnaire that rates perceived workload in order to assess the neurofeedback task. The participant rates, on a 20-point visual scale, each of the following aspects: mental demand, physical demand, temporal demand, performance, effort and frustration. Higher scores represent a higher task workload.	5 weeks
Secondary	7-Day Symptom Diary	Pain severity following 10 NF sessions (as measured by 7-Day Symptom Diary (Number Rating Scale between 0-10). A reduction in score represents better outcome.	5 weeks
Secondary	McGill Pain Questionnaire	Multidimensional pain questionnaire. Different types of pain are rated from 0-3 (none to severe pain). A reduction in score represents better outcome.	6 weeks
Secondary	Self-report of adverse events	Adverse events self-report after each NF session	5 weeks